Eli Lilly strikes deal with EU over Covid-19 antibody treatment

The pharmaceutical company will provide another 220,000 antibody doses for the treatment of Covid-19 patients.

Photo: Mike Blake/REUTERS / X00030

Eli Lilly has reached a procurement agreement with the EU to supply 220,00 doses of the US-based pharmaceutical company's antibody treatment for patients with Covid-19.

The Covid-19 treatment is a combination of two antibodies –bamlanivimab and etesevimab – which has shown itself to be effective in reducing the risk of hospitalization or death for people infected with Covid-19.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs